Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 9/20 | 0.58 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 4/20 | 0.56 |
| ▸ | LCK | P06239 | 3/20 | 0.56 |
| ▸ | KIT | P10721 | 3/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.56 |
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | AHR | P35869 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | SRC | P12931 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5668409 | 0.83 | PTGS1 (0.70) | PTGS1RXFP1P2RX1KDRLCK | |
| SCHEMBL12544169 | 0.79 | RXFP1 (0.88) | PTGS1RXFP1P2RX1SMN1; SMN2MEN1 | |
| SCHEMBL21854590 | 0.78 | RXFP1 (0.62) | PTGS1RXFP1P2RX1KDRLCK | |
| SCHEMBL4555402 | 0.77 | GAA (0.65) | PTGS1RXFP1KDRLCKKIT | |
| SCHEMBL23056302 | 0.77 | RXFP1 (0.61) | PTGS1RXFP1P2RX1KDRLCK | |
| SCHEMBL5014813 | 0.77 | LMNA (0.51) | PTGS1RXFP1KDRLCKKIT | |
| SCHEMBL29561761 | 0.77 | HTT (0.69) | PTGS1RXFP1P2RX1GAAMEN1 | |
| SCHEMBL16670141 | 0.77 | HTT (0.69) | PTGS1RXFP1P2RX1GAAMEN1 | |
| SCHEMBL29392990 | 0.76 | PTGS1 (1.00) | PTGS1RXFP1P2RX1GAAAHR | |
| SCHEMBL4031509 | 0.76 | PTGS1 (1.00) | PTGS1RXFP1P2RX1GAAAHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080188500-A1 | e.g. N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]-3-(trifluoromethyl)benzamide; Janus kinases inhibitor; anticarcinogenic agent; immune-related diseases, skin disorders, myeloid proliferative disorders | INCYTE CORPORATION | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188500-A1 | e.g. N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]-3-(trifluoromethyl)benzamide; Janus kinases inhibitor; anticarcinogenic agent; immune-related diseases, skin disorders, myeloid proliferative disorders | JAK3, JAK1, JAK2 | PTGS1 816/4885RXFP1 4578/4885P2RX1 2862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.